Drug intelligence / Profile preview

AIP-1

Development stage
Preclinical
Lead developer
Baylor College of Medicine
Modality
Recombinant Proteins and Enzymes
Administration
Intraperitoneal
01

Overview

AIP-1 (anti-inflammatory protein-1) is a recombinant, hookworm-derived protein with immunomodulatory properties. Originally identified as a tissue inhibitor of metalloproteases (TIMP)-like protein (Ac-TMP-1) secreted by the canine hookworm *Ancylostoma caninum*, as well as its human hookworm homolog *Necator americanus* (Na-AIP-1), AIP-1 does not possess metalloprotease inhibitory activity. Instead, it acts as an immunomodulator that promotes the accumulation of CD4+Foxp3+ regulatory T cells (Tregs) and stimulates the production of anti-inflammatory cytokines such as interleukin-10 (IL-10), transforming growth factor-beta (TGF-beta), and thymic stromal lymphopoietin (TSLP). AIP-1 has demonstrated preclinical efficacy in animal models of inflammatory bowel disease (colitis), rheumatoid arthritis, and Chagas disease-associated myocarditis and liver inflammation.

Other names
Ac-AIP-1Ac-AIP1Ac-AIP 1Ac-TIMP-1Ac-TIMP1Ac-TIMP 1Ac-TMP-1Ac-TMP1Ac-TMP 1Na-AIP-1Na-AIP1Na-AIP 1anti-inflammatory protein-1hookworm anti-inflammatory protein-1recombinant hookworm anti-inflammatory protein-1

Beyond the preview

Go deeper on AIP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP-1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call